{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:51:57Z","timestamp":1777578717863,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"crossref","award":["R309-A17835"],"award-info":[{"award-number":["R309-A17835"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"crossref","award":["R327-A19070"],"award-info":[{"award-number":["R327-A19070"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"crossref","award":["NNF20OC0065928"],"award-info":[{"award-number":["NNF20OC0065928"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"crossref","award":["NNF20OC0065928"],"award-info":[{"award-number":["NNF20OC0065928"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"crossref","award":["NNF20OC0065928"],"award-info":[{"award-number":["NNF20OC0065928"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Obesity, defined as Body Mass Index (BMI)\u2009\u2265\u200930\u00a0kg\/m<jats:sup>2<\/jats:sup>, is associated with inferior breast cancer prognosis, but its effect on neoadjuvant chemotherapy response is uncertain. We hypothesized that obesity decreases the odds of pathological complete response (pCR) after neoadjuvant chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We assembled a cohort of women with breast cancer who underwent neoadjuvant chemotherapy and subsequent surgery between January 1, 2016, and December 31, 2020, in Denmark. Patients received six or eight series of EC-TAX (epirubicin, cyclophosphamide, and paclitaxel) based on disease stage. Trastuzumab and pertuzumab were also used for patients with HER2+ disease. BMI was assessed as a categorical variable (normal weight (BMI\u2009=\u200918.5-&lt;25\u00a0kg\/m<jats:sup>2<\/jats:sup>), overweight (BMI\u2009=\u200925-&lt;30\u00a0kg\/m<jats:sup>2<\/jats:sup>), and obesity (BMI\u2009\u2265\u200930\u00a0kg\/m<jats:sup>2<\/jats:sup>)) and as a continuous variable. We used multivariable logistic regression models to compute odds ratios (ORs) for pCR after neoadjuvant chemotherapy according to BMI groups, using normal weight as reference, and stratified by menopausal, estrogen receptor (ER), and HER2 status. We adjusted for age and menopausal status based on a directed acyclic graph.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 1819 patients, 417 had pCR. Patients with overweight (<jats:italic>N<\/jats:italic>\u2009=\u2009585) or obesity (<jats:italic>N<\/jats:italic>\u2009=\u2009450) had 22% and 27% lower odds, respectively, of pCR (OR<jats:sub>adj<\/jats:sub>=0.78 [95%CI\u2009=\u20090.60-1.00] and OR<jats:sub>adj<\/jats:sub>=0.73 [95%CI\u2009=\u20090.55\u20130.97]) compared with patients with normal weight (<jats:italic>N<\/jats:italic>\u2009=\u2009784). In ER\/HER2-stratified analyses, we observed lower pCR odds among women with obesity and HER2+ tumors (OR<jats:sub>adj<\/jats:sub>=0.72 [95%CI\u2009=\u20090.47\u20131.12]) compared with their normal weight counterparts, but no notable association appeared for ER+\/HER2- (OR<jats:sub>adj<\/jats:sub>=0.97 [95%CI\u2009=\u20090.49\u20131.96]) and ER-\/HER2- tumors (OR<jats:sub>adj<\/jats:sub>=0.88 [95%CI\u2009=\u20090.49\u20131.57]). In analyses stratified by menopausal status, obesity was associated with lower pCR odds among postmenopausal women (OR<jats:sub>adj<\/jats:sub>=0.62 [95%CI\u2009=\u20090.41\u20130.94]), and, to a lesser extent, premenopausal women (OR<jats:sub>adj<\/jats:sub>=0.86 [95%CI\u2009=\u20090.58\u20131.27]).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our findings suggest that breast cancer patients with overweight or obesity have lower odds of pCR compared with patients with normal weight. As the results varied by ER and HER2 status, the observed association may depend on subtype. In summary, our results are consistent with earlier studies that propose BMI as a potential prognostic marker of pCR.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13058-025-02083-w","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T13:45:08Z","timestamp":1752241508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The association between body mass index and neoadjuvant chemotherapy response in patients with breast cancer"],"prefix":"10.1186","volume":"27","author":[{"given":"Jonas Busk","family":"Holm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stine Blaabjerg","family":"Skovbjerg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne Melgaard","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peer","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens Meldgaard","family":"Bruun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Alsner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deirdre","family":"Cronin-Fenton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Signe","family":"Borgquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"12","key":"2083_CR1","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","volume":"5","author":"C Fitzmaurice","year":"2019","unstructured":"Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, et al. Global, regional, and National Cancer incidence, mortality, years of life lost, years lived with disability, and Disability-Adjusted life-Years for 29 Cancer groups, 1990 to 2017. JAMA Oncol. 2019;5(12):1749\u201368.","journal-title":"JAMA Oncol"},{"issue":"3","key":"2083_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2083_CR3","unstructured":"World Health Organization. Obesity and overweight. 2024 [cited 2025 Mar 13]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"issue":"1","key":"2083_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2010.29.7614","volume":"29","author":"M Ewertz","year":"2011","unstructured":"Ewertz M, Jensen MB, Gunnarsd\u00f3ttir K\u00c1, H\u00f8jris I, Jakobsen EH, Nielsen D, et al. Effect of obesity on prognosis after Early-Stage breast Cancer. J Clin Oncol. 2011;29(1):25\u201331.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2083_CR5","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","volume":"25","author":"DSM Chan","year":"2014","unstructured":"Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901\u201314.","journal-title":"Ann Oncol"},{"key":"2083_CR6","unstructured":"American Association for Cancer Research. Preventing cancer: Identifying risk factors. 2022 [cited 2025 Mar 9]. Available from: https:\/\/cancerprogressreport.aacr.org\/progress\/cpr22-contents\/cpr22-preventing-cancer-identifying-risk-factors\/"},{"issue":"2","key":"2083_CR7","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/curroncol28020127","volume":"28","author":"T Tse","year":"2021","unstructured":"Tse T, Sehdev S, Seely J, Gravel DH, Clemons M, Cordeiro E, et al. Neoadjuvant chemotherapy in breast cancer: review of the evidence and conditions that facilitated its use during the global pandemic. Curr Oncol Tor Ont. 2021;28(2):1338\u201347.","journal-title":"Curr Oncol Tor Ont"},{"issue":"1","key":"2083_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","volume":"19","author":"Long-term outcomes for","year":"2018","unstructured":"Long-term outcomes for. Neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27\u201339.","journal-title":"Lancet Oncol"},{"issue":"Suppl 5","key":"2083_CR9","doi-asserted-by":"publisher","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","volume":"26","author":"E Senkus","year":"2015","unstructured":"Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(Suppl 5):v8\u201330.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"11","key":"2083_CR10","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","volume":"23","author":"A Mamtani","year":"2016","unstructured":"Mamtani A, Barrio AV, King TA, Van Zee KJ, Plitas G, Pilewskie M, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases?? Results of a prospective study. Ann Surg Oncol. 2016;23(11):3467\u201374.","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 2","key":"2083_CR11","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.breast.2015.07.018","volume":"24","author":"S Loibl","year":"2015","unstructured":"Loibl S, Denkert C, von Minckwitz G. Neoadjuvant treatment of breast cancer\u2013Clinical and research perspective. Breast Edinb Scotl. 2015;24(Suppl 2):S73\u201377.","journal-title":"Breast Edinb Scotl"},{"issue":"5","key":"2083_CR12","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(5):778\u201385.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9938","key":"2083_CR13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372.","journal-title":"Lancet"},{"issue":"11","key":"2083_CR14","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1093\/annonc\/mdt350","volume":"24","author":"C Denkert","year":"2013","unstructured":"Denkert C, Loibl S, M\u00fcller BM, Eidtmann H, Schmitt WD, Eiermann W, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(11):2786\u201393.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2083_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2021.11.017","volume":"61","author":"DJ O\u2019Connor","year":"2022","unstructured":"O\u2019Connor DJ, Davey MG, Barkley LR, Kerin MJ. Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery-A systematic review and meta-analysis. Breast Edinb Scotl. 2022;61:1\u201310.","journal-title":"Breast Edinb Scotl"},{"key":"2083_CR16","doi-asserted-by":"publisher","unstructured":"Wang H, Zhang S, Yee D, Basu S, Beckwith H, Potter D et al. Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis. Breast Cancer. 2021 Jan 2 [cited 2021 Mar 19]; Available from: https:\/\/doi.org\/10.1007\/s12282-020-01194-w","DOI":"10.1007\/s12282-020-01194-w"},{"key":"2083_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.breast.2017.04.001","volume":"33","author":"A Farr","year":"2017","unstructured":"Farr A, Stolz M, Baumann L, Bago-Horvath Z, Oppolzer E, Pfeiler G, et al. The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy. Breast Edinb Scotl. 2017;33:153\u20138.","journal-title":"Breast Edinb Scotl"},{"issue":"6","key":"2083_CR18","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s12282-019-00974-3","volume":"26","author":"I Usiskin","year":"2019","unstructured":"Usiskin I, Li F, Irwin ML, Cartmel B, Sanft T. Association between pre-diagnosis BMI, physical activity, pathologic complete response, and chemotherapy completion in women treated with neoadjuvant chemotherapy for breast cancer. Breast Cancer Tokyo Jpn. 2019;26(6):719\u201328.","journal-title":"Breast Cancer Tokyo Jpn"},{"issue":"1","key":"2083_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13058-020-01356-w","volume":"22","author":"S Di Cosimo","year":"2020","unstructured":"Di Cosimo S, Porcu L, Agbor-Tarh D, Cinieri S, Franzoi MA, De Santis MC, et al. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. Breast Cancer Res BCR. 2020;22(1):115.","journal-title":"Breast Cancer Res BCR"},{"key":"2083_CR20","doi-asserted-by":"crossref","unstructured":"Iwase T, Parikh A, Dibaj SS, Shen Y, Shrimanker TV, Chainitikun S et al. The prognostic impact of body composition for locally advanced breast Cancer patients who received neoadjuvant chemotherapy. Cancers. 2021;13(4).","DOI":"10.3390\/cancers13040608"},{"issue":"1","key":"2083_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3233\/BD-210071","volume":"41","author":"D Aguiar","year":"2022","unstructured":"Aguiar D, Ros L, P\u00e9rez D, Croissier L, Mori M, Hern\u00e1ndez M, et al. Impact of body mass index on pathological complete response and survival of breast cancer patients receiving neoadjuvant chemotherapy. Breast Dis. 2022;41(1):351\u201361.","journal-title":"Breast Dis"},{"issue":"6","key":"2083_CR22","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/0284186X.2022.2055976","volume":"61","author":"I Skarping","year":"2022","unstructured":"Skarping I, Blaabjerg Pedersen S, F\u00f6rnvik D, Zackrisson S, Borgquist S. The association between body mass index and pathological complete response in neoadjuvant-treated breast cancer patients. Acta Oncol Stockh Swed. 2022;61(6):731\u20137.","journal-title":"Acta Oncol Stockh Swed"},{"issue":"3","key":"2083_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4274\/ejbh.galenos.2022.2022-2-5","volume":"18","author":"SP Somashekhar","year":"2022","unstructured":"Somashekhar SP, Jaiswal R, Kumar R, Ashok BC, Rakshit S, Rauthan A, et al. An overview of the impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast Cancer in a tertiary care centre in South India. Eur J Breast Health. 2022;18(3):271\u20138.","journal-title":"Eur J Breast Health"},{"issue":"3","key":"2083_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10549-022-06681-6","volume":"195","author":"L Lin","year":"2022","unstructured":"Lin L, Soesan M, van Balen DEM, Beijnen JH, Huitema ADR. The influence of body mass index on the tolerability and effectiveness of full-weight-based Paclitaxel chemotherapy in women with early-stage breast cancer. Breast Cancer Res Treat. 2022;195(3):325\u201331.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2083_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41523-023-00552-z","volume":"9","author":"L Chen","year":"2023","unstructured":"Chen L, Wu F, Chen X, Chen Y, Deng L, Cai Q, et al. Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis. NPJ Breast Cancer. 2023;9(1):46.","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"2083_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10549-023-07214-5","volume":"204","author":"H Wang","year":"2024","unstructured":"Wang H, Yee D, Potter D, Jewett P, Yau C, Beckwith H, et al. Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial. Breast Cancer Res Treat. 2024;204(3):589\u201397.","journal-title":"Breast Cancer Res Treat"},{"key":"2083_CR27","doi-asserted-by":"crossref","unstructured":"Guliyev M, Alan \u00d6, G\u00fcnalt\u0131l\u0131 M, Safarov S, Fidan MC, Alkan \u015een G et al. Obesity is an independent prognostic factor that reduced pathological complete response in operable breast Cancer patients. Med Kaunas Lith. 2024;60(12).","DOI":"10.3390\/medicina60121953"},{"key":"2083_CR28","doi-asserted-by":"crossref","unstructured":"Englisch JF, Englisch A, Dannehl D, Eissler K, Tegeler CM, Matovina S, et al. Impact of obesity on pathological complete remission in early stage breast cancer patients after neoadjuvant chemotherapy: a retrospective study from a German University breast center. Arch Gynecol Obstet. 2025;311(2):437\u201342.","DOI":"10.1007\/s00404-024-07786-7"},{"issue":"1","key":"2083_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10549-016-3918-5","volume":"159","author":"ET Warner","year":"2016","unstructured":"Warner ET, Ballman KV, Strand C, Boughey JC, Buzdar AU, Carey LA, et al. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective alliance clinical trials (A151426). Breast Cancer Res Treat. 2016;159(1):109\u201318.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2083_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-015-3287-5","volume":"150","author":"C Fontanella","year":"2015","unstructured":"Fontanella C, Lederer B, Gade S, Vanoppen M, Blohmer JU, Costa SD, et al. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat. 2015;150(1):127\u201339.","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"2083_CR31","doi-asserted-by":"publisher","first-page":"e41380","DOI":"10.1371\/journal.pone.0041380","volume":"7","author":"S Chen","year":"2012","unstructured":"Chen S, Chen CM, Zhou Y, Zhou RJ, Yu KD, Shao ZM. Obesity or overweight is associated with worse pathological response to neoadjuvant chemotherapy among Chinese women with breast cancer. PLoS ONE. 2012;7(7):e41380.","journal-title":"PLoS ONE"},{"issue":"4","key":"2083_CR32","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/02841860802059259","volume":"47","author":"S M\u00f8ller","year":"2008","unstructured":"M\u00f8ller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, et al. The clinical database and the treatment guidelines of the Danish breast Cancer cooperative group (DBCG); its 30-years experience and future promise. Acta Oncol Stockh Swed. 2008;47(4):506\u201324.","journal-title":"Acta Oncol Stockh Swed"},{"key":"2083_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2147\/CLEP.S99517","volume":"8","author":"K Antonsen","year":"2016","unstructured":"Antonsen K, Rosenstock CV, Lundstr\u00f8m LH. The Danish anaesthesia database. Clin Epidemiol. 2016;8:435\u20138.","journal-title":"Clin Epidemiol"},{"key":"2083_CR34","unstructured":"Sundhedsdatastyrelsen. National health registers. [cited 2025 Feb 10]. Available from: https:\/\/english.sundhedsdatastyrelsen.dk\/health-data-and-registers\/national-health-registers"},{"key":"2083_CR35","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2147\/CLEP.S179083","volume":"11","author":"M Schmidt","year":"2019","unstructured":"Schmidt M, Schmidt SAJ, Adelborg K, Sundb\u00f8ll J, Laugesen K, Ehrenstein V, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563\u201391.","journal-title":"Clin Epidemiol"},{"key":"2083_CR36","unstructured":"Danske Multidisciplin\u00e6re Cancer Grupper. Brystcancer. [cited 2025 Jan 23]. Brystcancer - Kliniske retningslinjer for Brystkr\u00e6ft. Available from: https:\/\/www.dmcg.dk\/Kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/brystcancer\/"},{"issue":"5","key":"2083_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"4","key":"2083_CR38","first-page":"290","volume":"67","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast Cancer-Major changes in the American joint committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(4):290\u2013303.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2083_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4132\/jptm.2019.11.03","volume":"54","author":"S Ahn","year":"2020","unstructured":"Ahn S, Woo JW, Lee K, Park SY. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 2020;54(1):34\u201344.","journal-title":"J Pathol Transl Med"},{"key":"2083_CR40","doi-asserted-by":"crossref","unstructured":"Sinn HP, Kreipe H. A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. Breast Care Basel Switz. 2013;8(2):149\u201354.","DOI":"10.1159\/000350774"},{"issue":"2","key":"2083_CR41","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10549-018-4853-4","volume":"171","author":"T Kogawa","year":"2018","unstructured":"Kogawa T, Fujii T, Fouad TM, Liu DD, Harano K, Masuda H, et al. Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes. Breast Cancer Res Treat. 2018;171(2):501\u201311.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"2083_CR42","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1038\/sj.bjc.6602235","volume":"91","author":"AE Ring","year":"2004","unstructured":"Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2004;91(12):2012\u20137.","journal-title":"Br J Cancer"},{"issue":"Suppl 2","key":"2083_CR43","first-page":"S85","volume":"63","author":"WC Zamboni","year":"2023","unstructured":"Zamboni WC, Charlab R, Burckart GJ, Stewart CF. Effect of obesity on the pharmacokinetics and pharmacodynamics of anticancer agents. J Clin Pharmacol. 2023;63(Suppl 2):S85\u2013102.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"2083_CR44","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","volume":"28","author":"M Untch","year":"2010","unstructured":"Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(12):2024\u201331.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"2083_CR45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa1111065","volume":"366","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366(4):299\u2013309.","journal-title":"N Engl J Med"},{"issue":"2","key":"2083_CR46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1470-2045(11)70397-7","volume":"13","author":"M Untch","year":"2012","unstructured":"Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13(2):135\u201344.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2083_CR47","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41574-024-01032-5","volume":"20","author":"J Lysaght","year":"2024","unstructured":"Lysaght J, Conroy MJ. The multifactorial effect of obesity on the effectiveness and outcomes of cancer therapies. Nat Rev Endocrinol. 2024;20(12):701\u201314.","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"2083_CR48","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1093\/annonc\/mdw315","volume":"27","author":"J Furlanetto","year":"2016","unstructured":"Furlanetto J, Eiermann W, Marm\u00e9 F, Reimer T, Reinisch M, Schmatloch S, et al. Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(11):2053\u20139.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"2083_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2009.07.031","volume":"314","author":"E Maury","year":"2010","unstructured":"Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010;314(1):1\u201316.","journal-title":"Mol Cell Endocrinol"},{"key":"2083_CR50","doi-asserted-by":"publisher","first-page":"174019","DOI":"10.1016\/j.ejphar.2021.174019","volume":"899","author":"Y Li","year":"2021","unstructured":"Li Y, Yu C, Deng W. Roles and mechanisms of adipokines in drug resistance of tumor cells. Eur J Pharmacol. 2021;899:174019.","journal-title":"Eur J Pharmacol"},{"key":"2083_CR51","doi-asserted-by":"crossref","unstructured":"Holm JB, Rosendahl AH, Borgquist S. Local biomarkers involved in the interplay between obesity and breast Cancer. Cancers. 2021;13(24).","DOI":"10.3390\/cancers13246286"},{"issue":"4","key":"2083_CR52","doi-asserted-by":"publisher","first-page":"load021","DOI":"10.1093\/lifemeta\/load021","volume":"2","author":"V Musale","year":"2023","unstructured":"Musale V, Wasserman DH, Kang L. Extracellular matrix remodelling in obesity and metabolic disorders. Life Metab. 2023;2(4):load021.","journal-title":"Life Metab"},{"issue":"1","key":"2083_CR53","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","volume":"6","author":"J Huang","year":"2021","unstructured":"Huang J, Zhang L, Wan D, Zhou L, Zheng S, Lin S, et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther. 2021;6(1):153.","journal-title":"Signal Transduct Target Ther"},{"issue":"18","key":"2083_CR54","first-page":"3342","volume":"48","author":"N Houssami","year":"2012","unstructured":"Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer Oxf Engl 1990. 2012;48(18):3342\u201354.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"10","key":"2083_CR55","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41574-024-01012-9","volume":"20","author":"E B\u00f6rgeson","year":"2024","unstructured":"B\u00f6rgeson E, Tavajoh S, Lange S, Jessen N. The challenges of assessing adiposity in a clinical setting. Nat Rev Endocrinol. 2024;20(10):615\u201326.","journal-title":"Nat Rev Endocrinol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02083-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02083-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02083-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T08:03:52Z","timestamp":1757232232000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-025-02083-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2083"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02083-w","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with Danish law, no consent from participants or ethics committee approval is needed for the usage of registry-based data in scientific studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JMB has been part of speakers bureaus and\/or received research support from Boehringer Ingelheim, Eli Lilly, MSD\/Merck, and Novo Nordisk. JBH, SBS, HMN, PC, JA, DCF, and SB have no personal conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}